Arcus Biosciences (NYSE:RCUS) Upgraded at Wall Street Zen

Posted by Brian Himes on Oct 6th, 2026

Wall Street Zen upgraded shares of Arcus Biosciences (NYSE:RCUS – Free Report) from a sell rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

A number of other research firms have also recently commented on RCUS. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Friday, July 17th. Wells Fargo & Company upped their price target on shares of Arcus Biosciences from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 6th. Truist Financial reissued a “buy” rating and issued a $40.00 price objective (up from $35.00) on shares of Arcus Biosciences in a research note on Tuesday, September 8th. Wedbush restated an “outperform” rating and set a $43.00 price objective on shares of Arcus Biosciences in a research report on Wednesday, September 30th. Finally, Morgan Stanley set a $23.00 target price on shares of Arcus Biosciences in a report on Monday, August 10th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Arcus Biosciences has an average rating of “Moderate Buy” and a consensus price target of $38.30.

Read Our Latest Stock Analysis on RCUS

Arcus Biosciences Stock Performance

Shares of RCUS opened at $24.73 on Friday. The business has a 50-day simple moving average of $27.76 and a two-hundred day simple moving average of $26.10. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 0.22. Arcus Biosciences has a 52 week low of $13.61 and a 52 week high of $31.74. The stock has a market cap of $3.15 billion, a price-to-earnings ratio of -6.34 and a beta of 0.94.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.17. The firm had revenue of $41.00 million for the quarter, compared to analysts’ expectations of $21.98 million. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%.The firm’s revenue was down 74.4% on a year-over-year basis. On average, analysts expect that Arcus Biosciences will post -3.53 EPS for the current year.

Insiders Place Their Bets

In related news, CAO Alexander Azoy sold 2,827 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $30.00, for a total transaction of $84,810.00. Following the sale, the chief accounting officer owned 39,581 shares of the company’s stock, valued at $1,187,430. This represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Juan C. Jaen sold 48,502 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $30.05, for a total transaction of $1,457,485.10. Following the transaction, the president owned 842,307 shares of the company’s stock, valued at $25,311,325.35. This trade represents a 5.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 71,396 shares of company stock valued at $2,116,613. 7.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arcus Biosciences

Several institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp purchased a new stake in Arcus Biosciences in the 2nd quarter worth about $16,741,000. Nicholas Investment Partners LP bought a new stake in Arcus Biosciences in the fourth quarter worth about $4,869,000. Legal & General Group Plc purchased a new position in shares of Arcus Biosciences during the second quarter valued at approximately $5,906,000. First Turn Management LLC purchased a new position in shares of Arcus Biosciences during the fourth quarter valued at approximately $13,467,000. Finally, Baker BROS. Advisors LP purchased a new position in shares of Arcus Biosciences during the fourth quarter valued at approximately $6,434,000. 92.89% of the stock is owned by institutional investors.

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc is a biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses a proprietary research platform to develop small-molecule and antibody-based therapies designed to target biological mechanisms involved in tumor growth and immune-system regulation.

Arcus’ oncology pipeline has included investigational therapies such as zimberelimab, an anti-PD-1 antibody; domvanalimab, an anti-TIGIT antibody; quemliclustat, a CD73 inhibitor; and etrumadenant, an adenosine receptor antagonist.